05:58 PM EDT, 07/31/2024 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) late Wednesday reported Q2 non-GAAP net income of $5.30 per diluted share, up from $4.51 a year earlier.

Analysts polled by Capital IQ expected $4.77.

Revenue for the quarter ended June 30 was $1.02 billion, compared with $957.3 million a year earlier.

Analysts expected $1 billion.

For 2024, the company is projecting non-GAAP EPS of $19.20 to $20.30 on revenue of $4 billion to $4.1 billion. Previously, the company expected full-year EPS of $18.15 to $19.35 on revenue of $4 billion to $4.2 billion.

Analysts polled by Capital IQ are looking for $18.53 and $4.05 billion, respectively.

Shares dropped nearly 2% in after-hours activity.

Price: 108.50, Change: -1.75, Percent Change: -1.59